Christian Gessner
Overview
Explore the profile of Christian Gessner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
530
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reinmuth N, Gessner C, Schichtl T, Schutte W, Hammerschmidt S, Schulz H, et al.
Cancer Treat Res Commun
. 2025 Mar;
43:100878.
PMID: 40023002
Background: Atezolizumab is the first approved PD-L1 inhibitor for patients with advanced non-small cell lung cancer (NSCLC) in Germany. This study aimed to assess effectiveness and safety of this checkpoint...
2.
Brusselle G, Blasi F, Gessner C, Kuna P, Wark P, Cappellini G, et al.
ERJ Open Res
. 2024 Oct;
10(5).
PMID: 39351383
Introduction: Inhaled corticosteroid/formoterol fumarate (ICS/FF) as needed is recommended by the Global Initiative for Asthma (GINA) as sole therapy in adults with mild asthma, with low-dose maintenance ICS plus short-acting...
3.
Lommatzsch M, Criee C, de Jong C, Gappa M, Gessner C, Gerstlauer M, et al.
Pneumologie
. 2024 Mar;
77(8):e3.
PMID: 38513695
No abstract available.
4.
Gessner P, Tessema B, Scholz M, Sack U, Boldt A, Kuhnapfel A, et al.
Front Immunol
. 2023 Sep;
14:1239097.
PMID: 37701442
Introduction: There are limited data on the influence of different anti-cancer therapies on lymphocyte subpopulations and their relationships to survival of non-small cell lung cancer (NSCLC) patients. This study aimed...
5.
Martinez F, Criner G, Gessner C, Jandl M, Scherbovsky F, Shinkai M, et al.
Am J Respir Crit Care Med
. 2023 Jul;
208(4):417-427.
PMID: 37411039
CFTR (cystic fibrosis transmembrane conductance regulator) dysfunction is associated with mucus accumulation and worsening chronic obstructive pulmonary disease (COPD) symptoms. The aim of this phase IIb dose-finding study was to...
6.
Lommatzsch M, Criee C, de Jong C, Gappa M, Gessner C, Gerstlauer M, et al.
Pneumologie
. 2023 Jul;
77(8):461-543.
PMID: 37406667
The management of asthma has fundamentally changed during the past decades. The present guideline for the diagnosis and treatment of asthma was developed for respiratory specialists who need detailed and...
7.
Gessner C, Lommatzsch M
MMW Fortschr Med
. 2023 May;
165(11):44-49.
PMID: 37258838
No abstract available.
8.
Lommatzsch M, Gessner C
MMW Fortschr Med
. 2023 May;
165(11):5.
PMID: 37258813
No abstract available.
9.
Makharadze T, Quek R, Melkadze T, Gogishvili M, Ivanescu C, Giorgadze D, et al.
Cancer
. 2023 May;
129(14):2256-2265.
PMID: 37151113
Background: EMPOWER-Lung 3, a randomized 2:1 phase 3 trial, showed clinically meaningful and statistically significant overall survival improvement with cemiplimab plus platinum-doublet chemotherapy versus placebo plus chemotherapy for first-line treatment...
10.
van Zyl-Smit R, Chapman K, Kerstjens H, Gessner C, Sagara H, Tanase A, et al.
J Asthma Allergy
. 2023 Jan;
16:123-134.
PMID: 36714049
Background: Once-daily, single-inhaler mometasone furoate/indacaterol acetate/glycopyrronium bromide (MF/IND/GLY, an ICS/LABA/LAMA) and MF/IND (an ICS/LABA) via Breezhaler have been approved for the maintenance treatment of patients with asthma inadequately controlled with...